AtaiBeckley (ATAI) Liabilities and Shareholders Equity (2020 - 2026)
AtaiBeckley (ATAI) recorded quarterly Liabilities and Shareholders Equity of $264.9 million in Q1 2026, down 9.51% quarter-over-quarter from $292.7 million in Q4 2025.
AtaiBeckley (ATAI) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
AtaiBeckley's Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $264.9 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $264.9 million; the TTM figure through Mar 2026 stood at $717.0 million (changed N/A YoY), while the FY2025 annual figure was $292.7 million, up 83.66% from the prior year.
- Liabilities and Shareholders Equity was $264.9 million for Q1 2026 at AtaiBeckley, down from $292.7 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $506.0 million in Q2 2021 to a low of $159.4 million in Q4 2024.
- The 5-year median for Liabilities and Shareholders Equity is $287.1 million (2023), against an average of $299.3 million.
- Biggest YoY gain for Liabilities and Shareholders Equity was 83.66% in 2025; the steepest drop was 83.66% in 2025.
- A 3-year view of Liabilities and Shareholders Equity shows it stood at $159.4 million in 2024, then jumped by 83.66% to $292.7 million in 2025, then slipped by 9.51% to $264.9 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $264.9 million (Q1 2026), $292.7 million (Q4 2025), and $159.4 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - | 264.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 264.88 Mn |
| Dec 31, 2025 | 292.72 Mn |
| Sep 30, 2025 | 239.82 Mn |
| Jun 30, 2025 | 189.20 Mn |
| Mar 31, 2025 | 195.78 Mn |
| Dec 31, 2024 | 159.39 Mn |
| Dec 31, 2024 | 159.39 Mn |
| Sep 30, 2024 | 197.52 Mn |
| Jun 30, 2024 | 215.78 Mn |
| Mar 31, 2024 | 269.12 Mn |
| Dec 31, 2023 | 293.48 Mn |
| Sep 30, 2023 | 308.22 Mn |
| Jun 30, 2023 | 253.60 Mn |
| Mar 31, 2023 | 280.72 Mn |
| Dec 31, 2022 | 305.44 Mn |
| Sep 30, 2022 | 342.60 Mn |
| Jun 30, 2022 | 348.94 Mn |
| Mar 31, 2022 | 383.73 Mn |
| Dec 31, 2021 | 414.17 Mn |
| Sep 30, 2021 | 484.11 Mn |